Simplified heterocyclic analogues of fluoxetine inhibit inducible nitric oxide production in lipopolysaccharide-induced BV2 cells

Biological and Pharmaceutical Bulletin

Volumn 34, Issue 4, 2011, Pages 538-544

  Park, Ju Young ^a   Kim, Seung Woo ^b   Lee, Ja Kyeong ^b   Im, Weon Bin ^a   Jin, Byung Kwan ^c   Yoon, Sung Hwa ^a  

^a Ajou University   (South Korea)

^b Inha University   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

Author keywords

BV2 cell; Fluoxetine analogue; Inducible nitric oxide synthase; Microglia; Nitric oxide

Indexed keywords

1 [3 PHENYL 3 [4 (TRIFLUOROMETHYL)PHENOXY]PROPYL] 1H IMIDAZOLE; 1 [3 PHENYL 3 [4 (TRIFLUOROMETHYL)PHENOXY]PROPYL]PIPERAZINE; 1 [3 PHENYL 3 [4 (TRIFLUOROMETHYL)PHENOXY]PROPYL]PIPERIDINE; 1 [3 PHENYL 3 [4 (TRIFLUOROMETHYL)PHENOXY]PROPYL]PYRROLIDINE; 1 METHYL 4 [3 PHENYL 3 [4 (TRIFLUOROMETHYL)PHENOXY]PROPYL]PIPERAZINE; 1 PHENYL 3 (PIPERIDIN 1 YL)PROPAN 1 OL; 1 PHENYL 3 (PYRROLIDIN 1 YL)PROPAN 1 OL; 2 MORPHOLINO 1 PHENYLETHANONE; 3 (1H IMIDAZOL 1 YL) 1 PHENYLPROPAN 1 OL; 3 (4 METHYLPIPERAZIN 1 YL) 1 PHENYLPROPAN 1 OL; 3 IODO 1 PHENYLPROPAN 1 ONE; 3 MORPHOLINO 1 PHENYLPROPAN 1 OL; 3 MORPHOLINO 1 PHENYLPROPAN 1 ONE; 3 MORPHOLINO 1 PHENYLPROPAN 1 ONE 2 BENZYL OXIME; 3 MORPHOLINO 1 PHENYLPROPAN 1 ONE 2 ETHYL OXIME; 3 MORPHOLINO 1 PHENYLPROPAN 1 ONE OXIME; 4 [3 PHENYL 3 [4 (TRIFLUOROMETHYL)PHENOXY]PROPYL]MORPHOLINE; 4 IODO 1 PHENYLBUTAN 1 ONE; 4 MORPHOLINO 1 PHENYLBUTAN 1 ONE; FLUOXETINE; HETEROCYCLIC COMPOUND; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; PHENACYL BROMIDE; TERT BUTYL 4 (3 HYDROXY 3 PHENYLPROPYL)PIPERAZINE 1 CARBOXYLATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; HETEROCYCLIC COMPOUNDS; LIPOPOLYSACCHARIDES; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RNA, MESSENGER;

EID: 79953802072     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.34.538     Document Type: Article

References (30)

1. Meng X. L., Yang J. Y., Chen G. L., Zhang L. J., Wang L. H., Li J., Wang J. M., Wu C. F., Int. Immunopharmacol., 8, 1074-1082 (2008).
2. Blaylock R. L., Journal of American Physicians and Surgeons, 9, 46-51 (2004).
3. Takeuchi H., Mizuno T., Zhang G., Wang J., Kawanokuchi J., Kuno R., Suzumura A., J. Biol. Chem., 280, 10444-10454 (2005).
4. Gehrmann J., Matsumoto Y., Kreutzberg G. W., Brain Res. Rev., 20, 269-287 (1995).
5. Banati R. B., Gehrmann J., Schubert P., Kreutzberg G. W., Glia, 7, 111-118 (1993).
6. Moon D., Choi Y. H., Kim N., Park Y., Kim G., Int. Immunopharmacol., 7, 506-514 (2007).
7. Jin C., Moon D., Lee K., Kim M., Lee J., Choi Y. H., Park Y., Kim G., Pharmacol. Res., 54, 461-467 (2006).
8. Jantzen P. T., Connor K. E., Dicarlo G., Wenk G. L., Wallace J. L., Rojiani A. M., Coppola D., Morgan D., Gordon M. N., J. Neurosci., 22, 2246-2254 (2002).
9. Takeuchi H., Wang J., Kawanokuchi J., Mitsuma N., Mizuno T., Suzumura A., Neurobiol. Dis., 22, 33-39 (2006).
10. Chen R., Chen T., Chen T., Lin L., Chang C., Chang H., Wu C., Ann. N.Y. Acad. Sci., 1042, 262-271 (2005).
11. Aktan F., Life Sci., 75, 639-653 (2004).
12. Rafi M. M., Yadav P. N., Reyes M., J. Food Sci., 72, S69-S74 (2007).
13. Cui Y., Zhang L., Zhang T., Luo D., Jia Y., Guo Z., Zhang Q., Wang X., Wang X., Clin. Exp. Pharmacol. Physiol., 37, 422-428 (2010).
14. Jung K. K., Lee H. S., Cho J. Y., Shin W. C., Rhee M. H., Kim T. G., Kang J. H., Kim S. H., Hong S., Kang S. Y., Life Sci., 79, 2022-2031 (2006).
15. Park Y., Koketsu M., Kim J. M., Yeo J., Ishihara H., Lee K., Kim S. Y., Kim C., Biol. Pharm. Bull., 26, 1657-1660 (2003).
16. Hou R. C., Chen H., Tzen J. T. C., Jeng K. G., Neuro Report, 14, 1815-1819 (2003).
17. Choi S., Park Y., Choi D., Chang H., J. Microbiol. Biotechnol., 18, 1990-1996 (2008).
18. Abdel-Salam O. M. E., Baiuomy A. R., Arbid M. S., Pharmacol. Res., 49, 119-131 (2004).
19. Wilde M. I., Benfield P., Pharmacoeconomics, 13, 543-561 (1998).
20. Zafir A., Banu N., Eur. J. Pharmacol., 572, 23-31 (2007).
21. Mostert J. P., Koch M. W., Heerings M., Heersema D. J., Keyser J. D., CNS Neurosci. Ther., 14, 153-164 (2008).
22. Lim C., Kim S., Park J., Kim C., Yoon S., Lee J., J. Neurosci. Res., 87, 1037-1045 (2009).
23. Synder H. R., Brewster J. M., J. Am. Chem. Soc., 70, 4230-4232 (1948).
24. Yu Y., Kim J., Lee K., Kim S. Y., Han P., Lee J., Stroke, 36, 2238-2243 (2005).
25. Kim S., Jeong J., Kim H. J., Seo J., Han P., Yoon S., Lee J., Neurotox. Res., 17, 39-49 (2010).
26. Robertson D. W., Krushinski J. H., Fuller R. W., Leander J. D., J. Med. Chem., 31, 1412-1417 (1988).
27. Fotakis G., Timbrell J. A., Toxicol. Lett., 10, 171-177 (2006).
28. Dimmock J. R., Erciyas E., Raghavan S. K., Kirkpatrick D. L., Pharmazie, 45, 755-757 (1990).
29. Cazin M., Lesieur I., Boniface B., Boniface M., Lesieur D., Cazin J. C., Acta Therapeutica, 6, 205-211 (1980).
30. Huang Y., Hall I. H., Res. Commun. Pharmacol. Toxicol., 1, 17-38 (1996).